P0067 Basal cell markers for differentiation of prostate adenocarcinoma from cancer mimickers

Kalantari, Mahmoud Reza; Anvari, Kazem; Jabbari, Hasan; Tabrizi, Fatemeh Varshoee

doi:10.1016/j.ejca.2014.03.111

Cited by 6 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study we observed that P63 expression had high specificity and sensitivity in detection of prostatic adenocarcinoma. That is close to the results recorded by Kalantari et al [16].…”

Section: Diagnostic Performance Steap1 Expression C-myc Expression P6...supporting

confidence: 93%

The value of STEAP1, C-myc and P63 Immuno-expression in differentiation of prostatic carcinoma from its mimickers

Fayad

Emara

Ahmed

et al. 2019

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Prostatic adenocarcinoma is the 2 nd most common cancer in males. It is important to differentiate between prostatic adenocarcinoma and its benign mimickers with novel and reliable immunohistochemical markers for early diagnosis of prostatic adenocarcinoma, (6-transmembrane epithelial antigen of prostate (STEAP1), C-myc and basal cell marker P63 can be helpful in distinguishing prostatic adenocarcinoma from benign lesions. The aim of this study is to diagnose prostatic adenocarcinoma and differentiate it from its benign mimickers using STEAP1, C-myc and P63 immunoexpression and toevaluate the role of STEAP1 overexpression in prostate cancer initiation and progression. Methods: Retrospective cross-sectional study was conducted on 20 cases of prostatic adenocarcinoma, 8 cases of high grade prostatic intraepithelial neoplasia (HGPIN) and 18 cases of benign prostatic mimickers. All lesions were submitted for STEAP1, C-myc and P63 immunohistochemistry and the results were correlated with clinicopathological and histopathological parameters. Results: P63, STEAP1 and C-myc showed highly significant difference in expression in prostatic adenocarcinoma in relation to its benign mimickers (p-value<0.001). STEAP1 immunoexpression was significantly associated with Gleason score, grade grouping and perineural invasion of prostatic adenocarcinoma (p-value <0.05). Positive STEAP1 and Cmyc expression along with negative P63 showed high sensitivity (80.0%, 85.0% and 95.0%) respectively and considerable specificity (86.9%, 73.1% and 96.2%) respectively for differentiating between prostatic adenocarcinoma and its benign mimickers. Conclusion: STEAP1, C-myc and P63 immunoexpression was helpful in differentiation between prostatic adenocarcinoma and benign mimickers. STEAP1 may have a valuable prognostic role in prostatic adenocarcinoma.

show abstract

“…In our study we observed that P63 expression had high specificity and sensitivity in detection of prostatic adenocarcinoma. That is close to the results recorded by Kalantari et al [16].…”

Section: Diagnostic Performance Steap1 Expression C-myc Expression P6...supporting

confidence: 93%

The value of STEAP1, C-myc and P63 Immuno-expression in differentiation of prostatic carcinoma from its mimickers

Fayad

Emara

Ahmed

et al. 2019

Zagazig University Medical Journal

View full text Add to dashboard Cite

show abstract

“…The positivity rate of P63 is 100% in CaP with a strong reactivity with a poorly differentiated malignancy, this corresponds to previous works where p63 is 100% in pure benign lesions and adenocarcinoma. 20 All the reaction CaP cases were positive for P63 but in BPH only one case was positive.…”

Section: Discussionmentioning

confidence: 93%

Assessing the diagnostic impact of P63, PSA and BCL-2 proteins in premalignant and malignant prostate tissues

Ogunlayi,

Ekundina,

Kehinde

et al. 2024

Int J Sci Rep

View full text Add to dashboard Cite

Background: Prostate cancer (CaP) is increasingly becoming a major health issue affecting men as cancer-related fatalities are attributable to the condition. Immunohistochemistry (IHC) diagnostic criteria can help in gene-targeted therapy and help reduce its prevalence. This study is to assess the diagnostic impact of prostate-specific antigen (PSA), P63 and BCL-2 antibodies in CaP. Method: A case-controlled retrospective study was carried out on eighty (80) prostrate tissue blocks retrieved from the pathology archive of Ekiti State university teaching hospital Ado Ekiti. IHC analysis of the selected antibodies was carried out and also stained with haematoxylin and eosin (H and E) for second opinion and confirmation. Results: The study showed that all the CaP samples had 100% positivity with varying reactivity to the IHC biomarkers; PSA had 100% positivity and MPR of 94% due to its multiple weaknesses as a biomarker p63 is a basal cells marker. Conclusions: The expressions of these antibodies were observed in the progression of CaP. Although these markers are useful in predicting the progression from benign prostatic hyperplasia (BPH) to CaP, none of them can be utilised in isolation to a conclusion. Hence, they should be used in conjunction with one another to make up for their limitations. The immunohistochemical markers are beneficial in CaP diagnosis.

show abstract

“…While HMW-CK staining seems to be more sensitive than p63 in basal cell identification (90.70% vs. 88.37%, p = 0.7) [ 201 ], p63 still serves as a complementary marker in difficult cases [ 204 ]. A study by Kalantari MR et al [ 205 ] stated that although both HMW-CK and p63 presented high specificity and sensitivity in distinguishing true adenocarcinoma from benign lesions (BPH), p63 seemed to be more specific than HMW-CK in distinguishing PCa mimickers (such as adenosis, atrophy, and partial atrophy [ 206 ]) from adenocarcinoma. Although nuclear p63 staining, which is a negative marker for neoplasm, is usually observed in normal basal cells, there is a subset of PCa cancer cells for which cytoplasmic p63 staining is found [ 207 , 208 ].…”

Section: Biomarkersmentioning

confidence: 99%

Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives

et al. 2023

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most frequently diagnosed cancer in men. Despite the significant progress in cancer diagnosis and treatment over the last few years, the approach to disease detection and therapy still does not include histopathological biomarkers. The dissemination of PCa is strictly related to the creation of a premetastatic niche, which can be detected by altered levels of specific biomarkers. To date, the risk factors for biochemical recurrence include lymph node status, prostate-specific antigen (PSA), PSA density (PSAD), body mass index (BMI), pathological Gleason score, seminal vesicle invasion, extraprostatic extension, and intraductal carcinoma. In the future, biomarkers might represent another prognostic factor, as discussed in many studies. In this review, we focus on histopathological biomarkers (particularly CD169 macrophages, neuropilin-1, cofilin-1, interleukin-17, signal transducer and activator of transcription protein 3 (STAT3), LIM domain kinase 1 (LIMK1), CD15, AMACR, prostate-specific membrane antigen (PSMA), Appl1, Sortilin, Syndecan-1, and p63) and their potential application in decision making regarding the prognosis and treatment of PCa patients. We refer to studies that found a correlation between the levels of biomarkers and tumor characteristics as well as clinical outcomes. We also hypothesize about the potential use of histopathological markers as a target for novel immunotherapeutic drugs or targeted radionuclide therapy, which may be used as adjuvant therapy in the future.

show abstract

P0067 Basal cell markers for differentiation of prostate adenocarcinoma from cancer mimickers

Cited by 6 publications

References 0 publications

The value of STEAP1, C-myc and P63 Immuno-expression in differentiation of prostatic carcinoma from its mimickers

The value of STEAP1, C-myc and P63 Immuno-expression in differentiation of prostatic carcinoma from its mimickers

Assessing the diagnostic impact of P63, PSA and BCL-2 proteins in premalignant and malignant prostate tissues

Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives

Contact Info

Product

Resources

About